New Therapy For Parkinson s Disease Patients
Below is a MRR and PLR article in category Health Fitness -> subcategory Disease Illness.
New Hope for Parkinson’s Disease Patients
Exciting New Therapy Approval
In the U.S., around 1.5 million people suffer from Parkinson’s disease (PD), with over 60,000 new cases emerging each year. Fortunately, the FDA has recently approved a promising new treatment for those affected by this challenging condition.
Understanding Parkinson’s Disease
Parkinson's is a chronic, progressive disorder of the central nervous system, affecting both men and women equally, with no significant social, ethnic, or geographic boundaries. While it typically occurs after age 65, 40% of cases are diagnosed in individuals under 60. Although the exact cause remains unknown, effective management of symptoms is crucial, as there is currently no cure.
Limitations of Existing Treatments
Initially, levodopa/carbidopa is used to manage Parkinson’s symptoms. However, its effectiveness diminishes as the disease progresses, leading to periods where symptoms reappear, known as "off" time.
Introducing Zelapar: A New Solution
The FDA’s approval of Zelapar (selegiline HCl) Orally Disintegrating Tablets marks a breakthrough for patients whose symptoms worsen despite treatment with levodopa/carbidopa. Zelapar employs an innovative delivery system called Zydis Technology, allowing the tablets to dissolve quickly in the mouth and delivering more active medication at a lower dose. This has been shown to reduce "off" time by more than two hours daily.
Expert Endorsement
Dr. Cheryl Waters, from Columbia University, emphasizes the benefits of Zelapar. "Many Parkinson’s patients struggle with inadequate control from current treatments. Zelapar’s unique formulation significantly reduces 'off' time, providing valuable hours back to patients."
Important Safety Information
Zelapar should not be used by individuals with known allergies to selegiline or any inactive ingredients. It can cause serious, sometimes fatal interactions with meperidine and other MAO inhibitors, leading to symptoms like coma, severe blood pressure changes, and respiratory depression. Care should be taken when combining it with other medications, such as dextromethorphan, as this can induce psychosis or unusual behavior.
Furthermore, Zelapar may amplify the side effects of levodopa, potentially exacerbating dyskinesia. Adjusting the levodopa dosage may help alleviate this issue.
In clinical trials, 5.2% of patients discontinued use due to adverse effects, compared to 1% taking a placebo. Common side effects include nausea, dizziness, pain, headache, insomnia, rhinitis, dyskinesia, skin issues, stomatitis, back pain, and dyspepsia. In pregnancy, Zelapar should be used only if the potential benefits justify the risks.
Conclusion
Zelapar offers new hope for Parkinson’s patients struggling with inadequate symptom control, making significant improvements in daily life possible. As always, patients should discuss treatment options thoroughly with their healthcare providers to determine the best approach for their individual needs.
You can find the original non-AI version of this article here: New Therapy For Parkinson s Disease Patients.
You can browse and read all the articles for free. If you want to use them and get PLR and MRR rights, you need to buy the pack. Learn more about this pack of over 100 000 MRR and PLR articles.